Biohaven BHVN Weighted Average Exercise Price of Vested and Expected to Vest Options

Weighted Average Exercise Price of Vested and Expected to Vest Options at other companies

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Operating income-$130.4M+41.1%

Net income-$130.5M+41.1%

EPS (diluted)-$0.88+59.4%

Balance sheet

See full

Cash & equivalents$277.1M+170%

Total debt$286.2M+706%

Total equity$129.5M-50.1%

Total assets$466.4M+1.6%

Cash flow

See full

Operating cash flow-$149.9M+9.2%

CapEx--100%

Free cash flow-$149.9M+9.5%

Valuation

See full

Market cap$2.25B-48.1%

Enterprise value$2.26B-46.3%

Returns & leverage

See full

Return on equity-333%+17.9pp

Debt / equity2.2×+2.1×

Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's weighted average exercise price of vested and expected to vest options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Biohaven's weighted average exercise price of vested and expected to vest options?: Biohaven (BHVN) reported weighted average exercise price of vested and expected to vest options of $18.84 in Q1 2026.
How has Biohaven's weighted average exercise price of vested and expected to vest options changed year-over-year?: Biohaven's weighted average exercise price of vested and expected to vest options decreased by 11.1% year-over-year, from $21.20 to $18.84.